13F Holdings
中文EN

PETV PetVivo Holdings, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1512922 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.5%
TTM net income YoY0.2%
TTM EPS YoY18.9%
Revenue 3-yr CAGR4.4%
Net income 3-yr CAGR—

Margins

Gross margin70.3%
Operating margin-796.7%
Net margin-798.7%
FCF margin-386.1%
EBITDA margin-769.4%

Returns

ROE-433.2%
ROA-235.4%
ROIC (approx.)-424.0%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets107.4%
Debt / equity—
Current ratio0.31x
Interest coverage-394.93x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-122.2%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$1.14M$1.13M$968,706$917,162$115,586
Cost of revenue$386,856$137,677$101,823$221,036$201,154
Gross profit$754,751$994,856$866,883$696,126-$85,568
R&D expense$1.42M$1.58M$1.40M$996,358$474,881
SG&A expense$4.33M$4.82M$6.69M$5.02M$3.15M
Operating income-$9.06M-$8.06M-$10.62M-$8.73M-$5.06M
Interest expense$12,667$6,138———
Pretax income-$10.47M-$8.40M-$10.96M-$8.72M-$5.01M
Net income-$10.47M-$8.40M-$10.96M-$8.72M-$5.01M
EBITDA-$8.55M-$7.88M-$10.49M-$8.62M-$4.99M
EPS (basic)-0.38-0.41-0.78-0.85-0.57
EPS (diluted)-0.38-0.41-0.78-0.85—
Weighted avg. shares (diluted)30.15M20.49M13.97M10.22M—
Banking
Net interest income—-$359,408-$6,463$15,844$9,853
Balance sheet
Cash & equivalents$200,782$227,689$87,403$475,314$6.11M
Short-term investments$150,000$150,000———
Receivables$100,843$60,573$18,669$86,689$2,596
Inventory$538,366$323,504$390,076$370,283$98,313
Current assets$1.71M$5.61M$1.04M$1.42M$6.76M
PP&E, net$448,881$766,874$821,656$630,852$311,549
Intangibles$20,509$23,725$30,099$38,649$48,452
Total assets$3.58M$9.34M$3.12M$2.44M$7.43M
Current liabilities$1.38M$4.32M$1.41M$1.45M$1.17M
Total liabilities$1.38M$5.12M$2.43M$1.71M$1.44M
Shareholders' equity$2.20M$4.22M$685,953$725,025$5.99M
Shares outstanding35.85M24.18M17.06M10.95M9.99M
Cash flow statement
Operating cash flow-$6.11M-$5.32M-$7.42M-$6.79M-$4.17M
Capital expenditure$7,734$63,434$309,104$423,934$154,030
Free cash flow-$6.12M-$5.39M-$7.73M-$7.22M-$4.33M
Investing cash flow$11,800-$563,434-$309,104-$423,934-$183,184
Financing cash flow$6.07M$6.03M$7.34M$1.59M$10.44M
Depreciation & amortization$511,457$174,590$126,850$114,434$65,153
Stock-based compensation$1.88M$1.11M$2.11M$1.46M$702,896

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.